查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573162

心血管藥物市場：按藥物類別、適應症、患者人口統計、最終用戶、給藥途徑、分銷管道 - 2025-2030 年全球預測

Cardiovascular Therapeutics Market by Drug Class, Indication, Patient Demographics, End-User, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年心血管治療市場價值為473.7億美元，預計2024年將達到507.1億美元，複合年成長率為7.48%，預計到2030年將達到785.1億美元。

心血管藥物市場包括各種旨在管理和減輕心臟和血管疾病的治療方法和藥物。由於老化、肥胖和生活方式改變等因素導致心血管疾病的盛行率增加，對有效治療方法的需求正在迅速增加。隨著全球健康意識的提高和醫療技術的進步，推動了藥物、手術設備和再生醫學的應用，對創新治療方法的需求也越來越大。典型的最終用戶包括醫院、診所、研究機構和製藥公司。該領域的成長主要受到技術進步的推動，例如新型療法、個人化醫療的發展以及微創手術的普及。治療機會存在於新興市場的開拓中，這些市場的醫療基礎設施正在快速發展，使用人工智慧進行預測分析，以及製定針對患者的治療計劃。公司應專注於策略夥伴關係和研發投資，以利用這些趨勢。然而，高昂的開發成本、嚴格的法規環境以及某些治療方法的潛在副作用等挑戰可能會阻礙成長。某些地區缺乏成本和無法獲得先進醫療服務，也阻礙了市場滲透。創新機會包括基因治療、使用巨量資料分析進行患者分析，以及開發生物可吸收支架和智慧型穿戴裝置來監測心血管健康。競爭激烈且快速發展的市場需要市場相關人員不斷創新和適應。公司必須注重消費者教育並進行全面的臨床試驗，以確保安全性和有效性，並開發具有成本效益的解決方案並加強全球影響力。解決這些多方面的挑戰將使公司處於心血管藥物市場的前沿。

主要市場統計
基準年[2023] 473.7億美元
預測年份 [2024] 507.1億美元
預測年份 [2030] 785.1億美元
複合年成長率（%） 7.48%

市場動態：快速發展的心血管治療市場的關鍵市場洞察

供需的動態交互作用正在改變心血管藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 心血管疾病盛行率的增加和人口老化推動了對先進治療的需求
    • 心血管治療領域的技術進步與創新推動市場成長
    • 醫療支出的增加和政府的支持政策推動市場擴張
    • 心血管疾病早期診斷和治療意識的提高推動市場成長
  • 市場限制因素
    • 患者和初級保健提供者對心血管疾病及其治療的認知和理解較低
    • 與心血管藥物相關的副作用和不良反應使患者和醫療保健提供者對採用新療法猶豫不決
  • 市場機會
    • 透過積極的全球行銷策略擴大心血管疾病新型基因療法的覆蓋範圍
    • 人工智慧驅動的精準醫療可改善複雜心血管疾病的治療效果
    • 透過與生技公司的策略聯盟加速先鋒心血管療法的開發
  • 市場挑戰
    • 複雜的臨床試驗設計和嚴格的要求延長了心血管藥物的核准時間
    • 影響心血管研發投資的財務永續性和盈利挑戰

波特五力戰略工具駕馭心血管藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解心血管藥物市場的外部影響

外部宏觀環境因素對心血管藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解心血管治療藥物市場的競爭狀況

對心血管治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 心血管治療市場定位矩陣供應商績效評估

FPNV定位矩陣是評估心血管治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃心血管治療藥物市場的成功之路

心血管藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病的增加和人口老化正在推動對先進治療的需求
      • 心血管治療領域的技術進步與創新推動市場成長
      • 醫療成本上升和政府支持政策推動市場擴張
      • 對心血管疾病早期診斷和治療的認知不斷提高推動市場成長
    • 抑制因素
      • 患者和基層醫療提供者對心血管疾病及其治療的認知和理解有限
      • 與心血管藥物相關的副作用和不良反應使患者和醫療保健專業人員對引入新治療方法猶豫不決。
    • 機會
      • 透過積極的全球行銷策略擴大心血管疾病新基因療法的覆蓋範圍
      • 利用人工智慧驅動的精準醫療改善複雜心血管疾病的治療效果
      • 與生技公司建立策略夥伴關係，加速先鋒心血管療法的開發
    • 任務
      • 複雜的臨床試驗設計和嚴格的要求意味著心血管疾病藥物的核准時間較長
      • 影響心血管研究和開發投資的財務永續性和盈利挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按藥物類別分類的心血管藥物市場

  • 抗高血壓藥
    • BETA受體阻斷劑
    • 鈣離子通道阻斷劑
    • 腎素-血管收縮素系統抑制劑
      • ACE抑制劑
      • 血管收縮素II受體阻斷劑
  • 抗血栓藥
    • 抗凝血物
    • 抗血小板藥
    • 溶栓劑
  • 降血脂藥
    • 貝特類
    • 菸鹼酸
    • 他汀類藥物

第7章依適應症分類的心血管藥物市場

  • 心絞痛
  • 心臟衰竭
  • 高血脂症
  • 高血壓
  • 心肌梗塞
  • 中風

第8章心血管藥物市場患者細分

  • 成人用
  • 老年病
  • 小兒科

第9章心血管藥物市場：依最終用戶分類

  • 診所
  • 緊急服務
  • 家庭護理設置
  • 醫院

第10章心血管藥物市場：依給藥途徑

  • 口服
  • 胃腸外的
    • 肌肉注射
    • 靜脈
  • 經皮的

第11章心血管藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章美洲心血管藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區心血管藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲心血管藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C02DF

The Cardiovascular Therapeutics Market was valued at USD 47.37 billion in 2023, expected to reach USD 50.71 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 78.51 billion by 2030.

The cardiovascular therapeutics market encompasses a range of treatments and medications aimed at managing and mitigating heart and blood vessel disorders. With an increasing prevalence of cardiovascular diseases due to factors like aging populations, obesity, and lifestyle changes, the demand for effective therapeutics is burgeoning. The necessity for innovative treatments is amplified by rising global health awareness and advancements in medical technology, fostering applications across pharmaceuticals, surgical devices, and regenerative medicine. Key end-users include hospitals, clinics, research institutions, and pharmaceutical companies. Growth in this sector is primarily driven by technological advancements such as the development of novel therapeutics, personalized medicine, and the surge in minimally invasive procedures. Opportunities lie in the expansion of emerging markets where healthcare infrastructure is undergoing rapid development and in leveraging AI for predictive analytics and patient-specific treatment plans. Companies should focus on strategic partnerships and investments in R&D to capitalize on these trends. However, challenges such as high development costs, stringent regulatory environments, and potential side effects of some treatments can pose hurdles to growth. Another limitation is the lack of affordability and access to advanced healthcare services in certain regions, which can hinder widespread market penetration. Innovation opportunities include gene therapies, the use of big data analytics for patient profiling, and the development of bioabsorbable stents and smart wearable devices for monitoring cardiovascular health. The nature of the market is highly competitive and rapidly evolving, necessitating continuous innovation and adaptability from market players. Companies should focus on consumer education and conducting comprehensive clinical trials to ensure safety and efficacy, alongside developing cost-effective solutions to enhance global reach. By addressing these multifaceted challenges, businesses can position themselves at the forefront of the cardiovascular therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 47.37 billion
Estimated Year [2024] USD 50.71 billion
Forecast Year [2030] USD 78.51 billion
CAGR (%) 7.48%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiovascular Therapeutics Market

The Cardiovascular Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cardiovascular diseases and aging population driving demand for advanced treatments
    • Technological advancements and innovation in cardiovascular therapeutics fostering market growth
    • Rising healthcare expenditure and supportive government policies boosting market expansion
    • Growing awareness about early diagnosis and treatment of cardiovascular conditions propelling market growth
  • Market Restraints
    • Limited awareness and understanding of cardiovascular diseases and their treatments among patients and primary care providers
    • Side effects and adverse reactions associated with cardiovascular therapeutics create hesitation among patients and healthcare providers to adopt new treatments
  • Market Opportunities
    • Expanding the reach of novel gene therapies for cardiovascular diseases through aggressive global marketing strategies
    • Leveraging AI-driven precision medicine to enhance treatment outcomes for complex cardiovascular conditions
    • Forming strategic collaborations with biotechnological firms to accelerate the development of pioneering cardiovascular drugs
  • Market Challenges
    • Complex clinical trial designs and stringent requirements leading to prolonged timeframes for cardiovascular drug approvals
    • Financial sustainability and profitability challenges impacting investments in cardiovascular research and development

Porter's Five Forces: A Strategic Tool for Navigating the Cardiovascular Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiovascular Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiovascular Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiovascular Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiovascular Therapeutics Market

A detailed market share analysis in the Cardiovascular Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiovascular Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiovascular Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiovascular Therapeutics Market

A strategic analysis of the Cardiovascular Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, Biotronik SE & Co. KG, Boston Scientific Corporation, Bristol-Myers Squibb Company, C. R. Bard, Inc., Cardinal Health, Inc., Edwards Lifesciences Corporation, Getinge AB, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Terumo Corporation, and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antihypertensive Drugs, Antithrombotic Drugs, and Lipid-Lowering Drugs. The Antihypertensive Drugs is further studied across Beta Blockers, Calcium Channel Blockers, and Renin-Angiotensin System Inhibitors. The Renin-Angiotensin System Inhibitors is further studied across ACE Inhibitors and Angiotensin II Receptor Blockers. The Antithrombotic Drugs is further studied across Anticoagulants, Antiplatelet Agents, and Thrombolytics. The Lipid-Lowering Drugs is further studied across Fibrates, Niacin, and Statins.
  • Based on Indication, market is studied across Angina Pectoris, Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, and Stroke.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Clinics, Emergency Services, Homecare Settings, and Hospitals.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Transdermal. The Parenteral is further studied across Intramuscular and Intravenous.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cardiovascular diseases and aging population driving demand for advanced treatments
      • 5.1.1.2. Technological advancements and innovation in cardiovascular therapeutics fostering market growth
      • 5.1.1.3. Rising healthcare expenditure and supportive government policies boosting market expansion
      • 5.1.1.4. Growing awareness about early diagnosis and treatment of cardiovascular conditions propelling market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and understanding of cardiovascular diseases and their treatments among patients and primary care providers
      • 5.1.2.2. Side effects and adverse reactions associated with cardiovascular therapeutics create hesitation among patients and healthcare providers to adopt new treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding the reach of novel gene therapies for cardiovascular diseases through aggressive global marketing strategies
      • 5.1.3.2. Leveraging AI-driven precision medicine to enhance treatment outcomes for complex cardiovascular conditions
      • 5.1.3.3. Forming strategic collaborations with biotechnological firms to accelerate the development of pioneering cardiovascular drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex clinical trial designs and stringent requirements leading to prolonged timeframes for cardiovascular drug approvals
      • 5.1.4.2. Financial sustainability and profitability challenges impacting investments in cardiovascular research and development
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiovascular Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antihypertensive Drugs
    • 6.2.1. Beta Blockers
    • 6.2.2. Calcium Channel Blockers
    • 6.2.3. Renin-Angiotensin System Inhibitors
      • 6.2.3.1. ACE Inhibitors
      • 6.2.3.2. Angiotensin II Receptor Blockers
  • 6.3. Antithrombotic Drugs
    • 6.3.1. Anticoagulants
    • 6.3.2. Antiplatelet Agents
    • 6.3.3. Thrombolytics
  • 6.4. Lipid-Lowering Drugs
    • 6.4.1. Fibrates
    • 6.4.2. Niacin
    • 6.4.3. Statins

7. Cardiovascular Therapeutics Market, by Indication

  • 7.1. Introduction
  • 7.2. Angina Pectoris
  • 7.3. Heart Failure
  • 7.4. Hyperlipidemia
  • 7.5. Hypertension
  • 7.6. Myocardial Infarction
  • 7.7. Stroke

8. Cardiovascular Therapeutics Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Cardiovascular Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Emergency Services
  • 9.4. Homecare Settings
  • 9.5. Hospitals

10. Cardiovascular Therapeutics Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Oral
  • 10.3. Parenteral
    • 10.3.1. Intramuscular
    • 10.3.2. Intravenous
  • 10.4. Transdermal

11. Cardiovascular Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Americas Cardiovascular Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Cardiovascular Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Cardiovascular Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Bayer AG
  • 5. Biotronik SE & Co. KG
  • 6. Boston Scientific Corporation
  • 7. Bristol-Myers Squibb Company
  • 8. C. R. Bard, Inc.
  • 9. Cardinal Health, Inc.
  • 10. Edwards Lifesciences Corporation
  • 11. Getinge AB
  • 12. GlaxoSmithKline plc
  • 13. Johnson & Johnson
  • 14. Medtronic plc
  • 15. Merck & Co., Inc.
  • 16. Novartis AG
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. Terumo Corporation
  • 20. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. CARDIOVASCULAR THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CARDIOVASCULAR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CARDIOVASCULAR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIOVASCULAR THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY NIACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY EMERGENCY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MIL